Tus kws kho mob
P53-17 New Drug-Related Prior Authorization Requirements for Edaravone (Radicava) and Cerliponase Alfa (Brineura)
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 10, 2017
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 3231 - 3240 ntawm 3669
Tus kws kho mob
P58-16 Changes to Prior Authorization for Infertility for Commercial Lines of Business
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 28, 2016
Tus kws kho mob
P6-18 Addition of Drug to the Self-Administered Oncology PA with QL Program
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P3-17 Added Reimbursement Policies
Hnub Tim pib siv tau lub khoos kas: Lub Ib Hlis Ntuj 27, 2017
Tus kws kho mob
P15-17 Change to Administration of Interpreter Services for MHCP Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 13, 2017
Tus kws kho mob
P51R1-17 Updated: Accountable Care Organization Product and Network Name Changes
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 15, 2017
Tus kws kho mob
P60-17 2018 Renewal Changes Summary for Institutional Providers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2017
Tus kws kho mob
P61-16 New Drug-Related Prior Authorization Criteria for Amitiza and Linzess
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 13, 2016
Tus kws kho mob
P52-16 DHS Guidelines for Mental Health-Targeted Case Management Services for MHCP Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 04, 2016
Tus kws kho mob
P63-17 New Drug-Related PA with Quantity Limit Criteria: Otezla (apremilast)
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017